CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/7595 |
Resumo: | Department of Microbiology and Immunology. Rega Institute for Medical Research. KU Leuven, Leuven, Belgium |
id |
CRUZ_b510a8fc4d254aad782339be9ed0a915 |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/7595 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Menezes, Soraya MariaDecanine, DanieleBrassat, DavidCunha, Antonio Ricardo KhouriSchnitman, Saul V.Kruschewsky, Ramon de AlmeidaLópez, GiovanniAlvarez, CarolinaTalledo, MichaelGotuzzo, EduardoVandamme, Anne-MiekeCastro Filho, Bernardo GalvãoLiblau, RolandWeyenbergh, Johan Van2014-05-09T13:13:34Z2014-05-09T13:13:34Z2014MENEZES, S. M. et al. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy tropical spastic paraparesis and multiple sclerosis. Journal of Neuroinflammation, v.11, n.18, p. 18, 2014.1742-2094https://www.arca.fiocruz.br/handle/icict/7595engBioMed CentralCD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleDepartment of Microbiology and Immunology. Rega Institute for Medical Research. KU Leuven, Leuven, BelgiumFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Integrado de Microbiologia e Imunoregulação. Salvador, BA, BrasilINSERM UMR and Pôle des Neurosciences. Hôpital Purpan. Université de Toulouse. Toulouse, FranceDepartment of Microbiology and Immunology. Rega Institute for Medical Research. KU Leuven, Leuven, Belgium / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Integrado de Microbiologia e Imunoregulação. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Integrado de Microbiologia e Imunoregulação. Salvador, BA, BrasilBahiana School of Medicine and Public Health. Salvador-Bahia, BrazilInstituto de Medicina Tropical Alexander von Humboldt. Universidad Peruana Cayetano Heredia. Lima, PeruDepartment of Microbiology and Immunology. Rega Institute for Medical Research. KU Leuven, Leuven, Belgium / Instituto de Medicina Tropical Alexander von Humboldt. Universidad Peruana Cayetano Heredia. Lima, PeruInstituto de Medicina Tropical Alexander von Humboldt. Universidad Peruana Cayetano Heredia. Lima, PeruInstituto de Medicina Tropical Alexander von Humboldt. Universidad Peruana Cayetano Heredia. Lima, Peru / Departamento de Medicina. Facultad de Medicina Alberto Hurtado. Universidad Peruana Cayetano Heredia. Lima, PeruDepartment of Microbiology and Immunology. Rega Institute for Medical Research. KU Leuven, Leuven, Belgium / Instituto de Higiene e Medicina Tropical. Centro de Malária e outras Doenças Tropicais and Unidade de Microbiologia. Universidade Nova de Lisboa. Lisbon, PortugalBahiana School of Medicine and Public Health. Salvador, BA, Brasil. / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, BrasilINSERM UMR and Pôle des Neurosciences. Hôpital Purpan. Université de Toulouse. Toulouse, FranceDepartment of Microbiology and Immunology. Rega Institute for Medical Research. KU Leuven, Leuven, Belgium / Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Integrado de Microbiologia e Imunoregulação. Salvador, BA, Brasil / Institute for Immunological Investigation (iii-INCT). São Paulo, SP, BrasilBACKGROUND: Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP. Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking. METHODS: Using flow cytometry, we quantified ex vivo and in vitro expression of CD80 and CD86 in PBMCs of healthy controls, HTLV-1-infected individuals with and without HAM/TSP, and MS patients. We hypothesized ex vivo CD80 and CD86 expressions and their in vitro regulation by interferon (IFN)-α/ß mirror similarities between HAM/TSP and MS and hence might reveal clinically useful biomarkers in HAM/TSP. RESULTS: Ex vivo expression of CD80 and CD86 in T and B cells increased in all HTLV-1 infected individuals, but with a selective defect for B cell CD86 upregulation in HAM/TSP. Despite decreased total B cells with increasing disease duration (p = 0.0003, r = -0.72), CD80+ B cells positively correlated with disease severity (p = 0.0017, r = 0.69) in HAM/TSP. B cell CD80 expression was higher in women with HAM/TSP, underscoring that immune markers can reflect the female predominance observed in most autoimmune diseases. In contrast to MS patients, CD80+ (p = 0.0001) and CD86+ (p = 0.0054) lymphocytes expanded upon in vitro culture in HAM/TSP patients. The expansion of CD80+ and CD86+ T cells but not B cells was associated with increased proliferation in HTLV-1 infection. In vitro treatment with IFN-ß but not IFN-α resulted in a pronounced increase of B cell CD86 expression in healthy controls, as well as in patients with neuroinflammatory disease (HAM/TSP and MS), similar to in vivo treatment in MS. CONCLUSIONS: We propose two novel biomarkers, ex vivo CD80+ B cells positively correlating to disease severity and CD86+ B cells preferentially induced by IFN-ß, which restores defective upregulation in HAM/TSP. This study suggests a role for B cells in HAM/TSP pathogenesis and opens avenues to B cell targeting (with proven clinical benefit in MS) in HAM/TSP but also CD80-directed immunotherapy, unprecedented in both HAM/TSP and MSNeuroinflammatory diseaseHTLV-1Multiple sclerosisInterferon-alpha/betaB cellCostimulatory CD80CD86HumanEx vivoDisease severityGenderinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALMenezes SM CD80+ and CD86+....pdfMenezes SM CD80+ and CD86+....pdfapplication/pdf1147929https://www.arca.fiocruz.br/bitstream/icict/7595/1/Menezes%20SM%20CD80%2b%20and%20CD86%2b....pdf9de312fc3a753bfa46f2fd2f8e2b44f5MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81914https://www.arca.fiocruz.br/bitstream/icict/7595/2/license.txt7d48279ffeed55da8dfe2f8e81f3b81fMD52TEXTMenezes SM CD80+ and CD86+....pdf.txtMenezes SM CD80+ and CD86+....pdf.txtExtracted texttext/plain80352https://www.arca.fiocruz.br/bitstream/icict/7595/5/Menezes%20SM%20CD80%2b%20and%20CD86%2b....pdf.txt152bf61de43ffe73b57b30c2b3e08288MD55THUMBNAILMenezes SM CD80+ and CD86+....pdf.jpgMenezes SM CD80+ and CD86+....pdf.jpgGenerated Thumbnailimage/jpeg2174https://www.arca.fiocruz.br/bitstream/icict/7595/4/Menezes%20SM%20CD80%2b%20and%20CD86%2b....pdf.jpgc40e900856f1eddb55bd5d70f8b6c963MD54icict/75952023-03-15 14:33:11.471oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:33:11Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis |
title |
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis |
spellingShingle |
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis Menezes, Soraya Maria Neuroinflammatory disease HTLV-1 Multiple sclerosis Interferon-alpha/beta B cell Costimulatory CD80 CD86 Human Ex vivo Disease severity Gender |
title_short |
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis |
title_full |
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis |
title_fullStr |
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis |
title_full_unstemmed |
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis |
title_sort |
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis |
author |
Menezes, Soraya Maria |
author_facet |
Menezes, Soraya Maria Decanine, Daniele Brassat, David Cunha, Antonio Ricardo Khouri Schnitman, Saul V. Kruschewsky, Ramon de Almeida López, Giovanni Alvarez, Carolina Talledo, Michael Gotuzzo, Eduardo Vandamme, Anne-Mieke Castro Filho, Bernardo Galvão Liblau, Roland Weyenbergh, Johan Van |
author_role |
author |
author2 |
Decanine, Daniele Brassat, David Cunha, Antonio Ricardo Khouri Schnitman, Saul V. Kruschewsky, Ramon de Almeida López, Giovanni Alvarez, Carolina Talledo, Michael Gotuzzo, Eduardo Vandamme, Anne-Mieke Castro Filho, Bernardo Galvão Liblau, Roland Weyenbergh, Johan Van |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Menezes, Soraya Maria Decanine, Daniele Brassat, David Cunha, Antonio Ricardo Khouri Schnitman, Saul V. Kruschewsky, Ramon de Almeida López, Giovanni Alvarez, Carolina Talledo, Michael Gotuzzo, Eduardo Vandamme, Anne-Mieke Castro Filho, Bernardo Galvão Liblau, Roland Weyenbergh, Johan Van |
dc.subject.en.pt_BR.fl_str_mv |
Neuroinflammatory disease HTLV-1 Multiple sclerosis Interferon-alpha/beta B cell Costimulatory CD80 CD86 Human Ex vivo Disease severity Gender |
topic |
Neuroinflammatory disease HTLV-1 Multiple sclerosis Interferon-alpha/beta B cell Costimulatory CD80 CD86 Human Ex vivo Disease severity Gender |
description |
Department of Microbiology and Immunology. Rega Institute for Medical Research. KU Leuven, Leuven, Belgium |
publishDate |
2014 |
dc.date.accessioned.fl_str_mv |
2014-05-09T13:13:34Z |
dc.date.available.fl_str_mv |
2014-05-09T13:13:34Z |
dc.date.issued.fl_str_mv |
2014 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
MENEZES, S. M. et al. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy tropical spastic paraparesis and multiple sclerosis. Journal of Neuroinflammation, v.11, n.18, p. 18, 2014. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/7595 |
dc.identifier.issn.none.fl_str_mv |
1742-2094 |
identifier_str_mv |
MENEZES, S. M. et al. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy tropical spastic paraparesis and multiple sclerosis. Journal of Neuroinflammation, v.11, n.18, p. 18, 2014. 1742-2094 |
url |
https://www.arca.fiocruz.br/handle/icict/7595 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
BioMed Central |
publisher.none.fl_str_mv |
BioMed Central |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/7595/1/Menezes%20SM%20CD80%2b%20and%20CD86%2b....pdf https://www.arca.fiocruz.br/bitstream/icict/7595/2/license.txt https://www.arca.fiocruz.br/bitstream/icict/7595/5/Menezes%20SM%20CD80%2b%20and%20CD86%2b....pdf.txt https://www.arca.fiocruz.br/bitstream/icict/7595/4/Menezes%20SM%20CD80%2b%20and%20CD86%2b....pdf.jpg |
bitstream.checksum.fl_str_mv |
9de312fc3a753bfa46f2fd2f8e2b44f5 7d48279ffeed55da8dfe2f8e81f3b81f 152bf61de43ffe73b57b30c2b3e08288 c40e900856f1eddb55bd5d70f8b6c963 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1822792023963336704 |